Promaxo Raises $4.17M – To Accelerate Data Strategy

January 13, 2021

Promaxo notes the funding was led by Huami Corporation.

Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, California, and backed by over 60 patents, the company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities.

With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient screening and interventions. The Company has formed numerous long-term and strategic partnerships with investor groups as it prepares to enter the US market.

As an industry, we are just scratching the surface of how powerful MRI is poised to become in guided interventions, and we are proud to have Huami as a strategic investor as we introduce our truly open MRI system to the masses,” said Dr. Amit Vohra, founder and CEO of Promaxo. “We are thrilled to have the financial support to help execute our vision and look forward to providing the best healthcare possible to our patients and clinical partners.”

The trailblazing medical technology company plans to use the funds to accelerate its data strategy as it continues to incorporate artificial intelligence in imaging and image-based interventions. Promaxo’s patient-centric approach will provide patients with cutting-edge technology as it works to expand the frontiers of knowledge in the fields of medical imaging, robotics, and artificial intelligence.

“Huami’s mission is to connect health with technology, and we see tremendous opportunity in imaging to expand our growth opportunities. Companies such as Promaxo are disrupting the locations, applications and costs of medical imaging. Huami has resources, such as miniaturization engineering expertise, that can help accelerate Promaxo’s scaling, growth and success, and we look forward to what our partnership can develop,” said Huami Chief Operating Officer Mike Yeung.

Promaxo and Huami will continue to explore a partnership for the application of artificial intelligence, product integration opportunities, and commercialization, making them a natural fit to serve as strategic partners.

SourcePromaxo
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy